



3A.

NON-SEXUALLY TRANSMITTED DISEASES


The infectious diseases designated as notifiable vary slightly by state. A notifiable disease is one for which regular, frequent, and timely information regarding individual cases is considered necessary for the prevention and control of the disease. All states generally report the internationally quarantinable diseases (i.e., cholera or plague) in compliance with the World Health Organization's International Health Regulations.

Data on morbidity, levels of disease, and disability in the Arizona population are obtained for certain infectious diseases that must be reported by law. The Bureau of Epidemiology and Disease Control Services conducts surveillance and monitoring of these reportable diseases and it provided data for the respective sections of this chapter and sections 5F, 6A, and 6B.

This section provides some illustrative findings from the tabulated data. It is not intended to be an exhaustive analysis of the incidence of infectious diseases in the State. There is more information available online on the website of the Office of Infectious Disease Services at: <http://azdhs.gov/phs/oids/index.htm>.

3A. NON-SEXUALLY TRANSMITTED DISEASES

Figure 3A-1
Trends in the Incidence Rates^a of Valley Fever (Coccidioidomycosis) by Year, Arizona, 2010-2020




Note: ^a Number of cases per 100,000 population.

Coccidioidomycosis or *Valley Fever* is a fungal infection caused by inhalation of airborne spores that are present in the soil of southwestern United States, California, and parts of Central and South America. Most infections are asymptomatic or self-limited in patients with healthy immune systems. In rare instances, severe lung disease or disseminated infection can develop in patients.

Valley Fever imposed the greatest burden on morbidity among all non-sexually transmitted, notifiable diseases in Arizona in 2020. The reported incidence of Valley Fever increased 11.2 percent from 2019 (n=10,358) to 2020 (n=11,523). The 2020 incidence rate of 160.6/100,000 (**Figure 3A-1, Table 5F-2**) was 11.5 percent greater than the incidence rate of 144.1/100,000 in 2019, but was 37.2 percent lower than the unprecedented incidence rate of 255.8/100,000 in 2011.

Figure 3A-2
Trends in Case Fatality Rates^a for Valley Fever (Coccidioidomycosis) by Year, Arizona, 2010-2020



Note: ^a Number of deaths per 100 reported cases.

Fifty-seven of the 11,523 Arizonans who had *Valley Fever* in 2020 died from it (**Table 3A-2**) for a case fatality rate of 0.5 deaths per 100 cases (**Figure 3A-2**). The 2020 case fatality rate for *Coccidioidomycosis* was 66.7 percent higher than in 2010.


3A. NON-SEXUALLY TRANSMITTED DISEASES

Shigellosis is an infectious disease caused by a group of bacteria called *Shigella* that can cause diarrhea in humans. To spread from one person to another, *Shigellae* can be transmitted through contaminated foods, sexual contact, and water used for drinking or recreational purposes.

From 2010–2020, *shigellosis* was the most common enteric disease to afflict Arizonans after *campylobacteriosis* and *salmonellosis* (**Table 3A-1**).

The number of reported cases of *shigellosis* has decreased by 173 cases from 426 in 2019 to 253 in 2020. Compared to 2019, the incidence rate of *shigellosis* was 40.7 percent lower at approximately 4 reported cases/100,000 population in 2020 (**Figure 3A-3**).

Figure 3A-3
Trends in the Incidence Rates^a of Shigellosis by Year, Arizona, 2010-2020




Note: ^a Number of reported cases per 100,000 population.

Figure 3A-4
Trends in the Incidence Rates^a of Salmonellosis^b by Year, Arizona, 2010-2020

Salmonellosis is a bacterial infection. Most of those who are infected with *Salmonella* develop diarrhea, fever, and abdominal cramps.


The incidence rate of *salmonellosis* decreased 33.8 percent from 13.3/100,000 in 2019 to 8.8/100,000 in 2020 (**Figure 3A-4**). The risk of *salmonellosis* was substantially higher in Navajo (26.2/100,000), Santa Cruz (20.9/100,000), Graham (15.5/100,000), Apache (15.1/100,000), Yavapai (14.8/100,000), and Pima (14.6/100,000), than the remaining counties (**Table 5F-2**).



Notes: ^a Number of reported cases per 100,000 population; ^b Excluding *S. Typhi* and *S. Paratyphi*.

3A. NON-SEXUALLY TRANSMITTED DISEASES

Figure 3A-5
Trends in the Incidence Rates^a of Hepatitis A by Year,
Arizona, 2010-2020




Note: ^a Number of reported cases per 100,000 population.

Hepatitis A is a liver disease caused by the *hepatitis A* virus. During 1995-1996, highly effective *hepatitis A* vaccines became available in the United States. Routine childhood vaccination for *hepatitis A* was recommended in 1999. The expansion of recommendations for routine *hepatitis A* vaccination to include all children in the United States aged 12-23 months is likely to reduce hepatitis rates further.

In Arizona, the incidence rate of *hepatitis A* was 0.8/100,000 in 2020, the highest rate recorded during the 2010-2020 period was 8.2 in 2019. The 2020 incidence rate was approximately 9 times lower than the 2019 rate (8.2/100,000; **Figure 3A-5**).

Figure 3A-6
Trends in the Incidence of Pulmonary Tuberculosis and Total Tuberculosis^a
by Year, Arizona, 2010-2020



Note: ^a Number of reported cases by year.

Tuberculosis (TB) is an infectious disease that usually attacks the lungs, but can attack almost any part of the body. Tuberculosis is spread from person to person through the air.

The number of reported cases of *pulmonary tuberculosis* decreased from 158 cases in 2019 to 112 reported cases in 2020. The number of reported cases of tuberculosis other than pulmonary increased from 18 in 2019 to 24 in 2020 cases (**Figure 3A-6, Table 3A-1**). The incidence rate of *total* tuberculosis changed in 2019 2.5/100,000 to 1.9/100,000 in 2020 (**Table 5F-2**).

Pulmonary tuberculosis accounted for 82.4 percent of all tuberculosis infections in 2020 (**Table 3A-1**). Fifteen Arizonans who had *tuberculosis* died from it in 2020, an increase from 9 in 2019 (**Table 3A-2**).